This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Hyaluronic acid in osteoarthritis of the knee

Authoring team

  • there is evidence that the beneficial effect is as least as good as achieved with NSAIDs but without the gastrointestinal side effects (1)
    • Huskisson and Donnelly, in a randomised, placebo, controlled trial of treatment of osteoarthritis of the knee, have shown that a course of 5 weekly hyaluronic acid injections can improve knee function for 4 months and reduce pain on walking for 6 months (1)
  • a more recent meta-analysis (2):
    • confirmed the therapeutic efficacy and safety of intra-articular injection of hyaluronic acid for the treatment of osteoarthritis of the knee
  • NICE however state that intra-articular hyaluronan injections are not recommended for the treatment of osteoarthritis (3)

Notes:

  • a study compared intra-articular hylan versus hyaluronic acid for osteoarthritis (4)
    • there was no evidence for a difference in efficacy between the two treatments
  • there is evidence that repeated cycles of intra-articular injections of hyaluronic acid not only improve knee osteoarthritis symptoms during the in-between cycle period but also exert a marked carry-over effect for at least 1 year after the last cycle (5)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.